PTH and hyperparathyroidism: Notably, PTH levels usually decrease, but persistent secondary hyperparathyroidism is described in 10 to 60% of patients 12 months post-KTx [27–29] with hyperparathyroidism being an independent risk factor for allograft dysfunction in pediatric KTx [30].